Mendiola MJ, Regalado VEL, Fernández-Calienes VA, Acuña RD, Rojas RL, Valdés IO

Language: Spanish
References: 21
Page: 244-255
PDF size: 226.87 Kb.

ABSTRACT

Introduction: the search of new antimalarial compounds comprises, among its challenges, the development of therapeutic alternatives for cerebral malaria; due to the high mortality and neurological deficiencies that persist after treatment with recommended drugs.
Objectives: to evaluate the activity of organic fractions of Mycale laxissima and Clathria echinata in the cerebral malaria model of infection of C57BL/6 mice with Plasmodium berghei ANKA.
Methods: preparative fractions of both species were obtained by reverse-phase flash chromatography. In order to detect the presence of saponins, triterpenods/steroids and alkaloids, a qualitative chemical analysis was performed. The schyzontocidal effect of the extracts was determined by the suppression test at the beginning of the infection. Survival, neurological symptoms and body weight changes were evaluated in subsequent days.
Results: the organic fractions of Mycale laxissima at 200 mg/kg and Clathria echinata at 100 mg/kg showed neither substantial reductions of body weights, nor deaths of animals until day 4; but caused significant reductions of median parasitemia of 45 % and 53 % respectively. The fraction of Mycale laxissima at 200 mg/kg caused a significant increase in the median survival time up to day 20, whereas animals treated with Clathria echinata at 100 mg/kg presented a survival of 16 days. Both increases the survival time 7 days. Neurological alterations were not observed in the groups treated with organic fractions when compared to the control group. This survival extension was similar to the effect of administration of 7.5 mg/kg of chloroquine.
Conclusions: the organic fractions of Mycale laxissima and Clathria echinata exhibited promising antimalarial activities in the infection model of C57BL/6 mice with Plasmodium berghei ANKA. This indicates that their active chemical constituents should be studied.

REFERENCES

1. World Health Organization. Global report on antimalarial drug efficacy and drug resistance: 2000-2010. Geneva: WHO Press; 2010.

2. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376(9753):1647-57.

3. World Health Organization. Guidelines for the treatment of malaria. Geneva: WHO Press; 2006.

4. White NJ, Turner GDH, Medana IM, Dondorp AM, Day NPJ. The murine cerebral malaria phenomenon. Trends Parasitol. 2009;26(1):11-5.

5. De Souza JB, Hafalla JCR, Riley EM, Couper KN. Cerebral malaria: why experimental murine models are required to understand the pathogenesis of disease. Parasitology. 2010;137(5):75572.

6. Wells TC. Natural products as starting points for future anti-malarial therapies: going back to our roots? Malar J. 2011;10(Suppl 1):S3.

7. Mendiola BJ, Regalado EL, Laguna A, Valdes O, Fernandez-Calienes A, Acuña D, et al. In vitro and in vivo inhibitory activities against Plasmodium berghei of Cuban marine sponges extracts. Vaccimonitor. 2010;19(Suppl 2):227.

8. Radad K, Moldzio R, Rausch WD. Ginsenosides and their CNS targets.CNS Neurosci Ther. 2011;17(6):761-8.

9. Yuan CS, Wang CZ, Wicks SM, Qi LW. Chemical and pharmacological studies of saponins with a focus on American ginseng. J Ginseng Res. 2010;34(3):160-7.

10. Ivanchina NV, Kicha AA, Stonik VA. Steroid glycosides from marine organisms. Steroids. 2011;76(5):425-54.

11. Laville R,Thomas OP, Berrue F, Marquez D, Vacelet J, Amade P. Bioactive guanidine alkaloids from two caribbean marine sponges. J Nat Prod. 2009;72(9):1589-94.

12. Berlinck RG, Burtoloso AC, Kossuga MH. The chemistry and biology of organic guanidine derivatives. Nat Prod Rep. 2008;25(5):919-54.

13. Regalado E, Laguna A, Mendiola J, Thomas O, Nogueiras C. Bromopyrrole alkaloids from the Caribbean sponge Agelas cerebrum. Quim Nova. 2011;34(2):289-91.

14. Harborne JB. Phytochemical methods. London: Chapman and Hall, Ltd; 1973.

15. Peters W, Portus JH, Robinson BL.The chemotherapy of rodent malaria. XXII. The value of drug-resistant strains of Plasmodium berghei in screening for blood schizontocidal activity. Ann Trop Med Parasitol. 1975;69(2):155-71.

16. Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, Ridley R. Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl Trop Dis. 2009;3(8):e440.

17. Waknine-Grinberg JH, Hunt N, Bentura-Marciano A, McQuillan JA, Chan HW, Chan WC, et al. Artemisone effective against murine cerebral malaria. Malar J. 2010;9:227-41.

18. Dai M, Reznik SE, Spray DC, Weiss LM, Tanowitz HB, Gulinello M, et al. Persistent cognitive and motor deficits after successful antimalarial treatment in murine cerebral malaria. Microbes Infect. 2010;12(14-15):1198-207.

19. Martins YC, Werneck GL, Carvalho LJ, Silva BP, Andrade BG, Souza TM, et al. Algorithms to predict cerebral malaria in murine models using the SHIRPA protocol. Malar J. 2010;9:85-97.

20. Mc Quillan JA, Mitchell AJ, Ho YF, Combes V, Ball HJ, Golenser J, et al. Coincident parasite and CD8 T cell sequestration is required for development of experimental cerebral malaria. Int J Parasitol. 2011;41(2):155-63.

21. Han H, Chen Y, Bi H, Yu L, Sun C, Li S, et al. In vivo antimalarial activity of ginseng extracts. Pharm Biol. 2011;49(3):283-9.